Gilead To License HCV Drug In Bid To Improve Access In Lower-Income Countries
News outlets report on Gilead’s agreement with Indian generic drugmakers to allow production of its hepatitis C medication.
Financial Times: Gilead in deal with India labs to produce Sovaldi
“Gilead Sciences will allow seven large Indian generic drug producers to make and sell its blockbuster hepatitis C drug Sovaldi in more than 90 developing countries, in a move it says will ensure affordable access to the potentially life-saving treatment…” (Kazmin/Ward, 9/15).
New York Times: Maker of Costly Hepatitis C Drug Sovaldi Strikes Deal on Generics for Poor Countries
“…The company intends to provide greater access to the medicine, Sovaldi, for most of the nearly 180 million infected worldwide with hepatitis C who do not live in rich countries. Some 350,000 people die every year of hepatitis C infections, most of them in middle- and low-income nations…” (Harris, 9/15).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.